Newsletter | May 6, 2025

05.06.25 -- Promising Clinical Trial Updates Shared At The American Academy Of Neurology Conference

FEATURED EDITORIAL

Promising Clinical Trial Updates Shared At The American Academy Of Neurology Conference

New treatment/targeting methods for Guillain-Barre Syndrome and Huntington’s Disease, CIDP, and ALS are seeing clinical trial success, according to updates shared at the 2025 American Academy of Neurology conference in early April.

INDUSTRY INSIGHTS

Innovative Technology For Developing, Scaling Peptide-Based Therapeutics

Watch as experts walk through several technologies and case studies, focusing on liquid-phase peptide synthesis, crystallization, method development for impurity analysis, and more.

Advanced Analytical Tools To De-Risk Pharmaceutical Development

Discover three tools that facilitate a successful journey from candidate compound to clinical triumph: solid form screening, PBPK modeling, and AI-enabled route scouting.

Solid Form Screening, Rapid Formulation Selection To Meet Tight Timelines

A comprehensive approach to evaluating drug molecules for the selection of a lead solid form and formulation can significantly accelerate development timelines and limit risks in later development.

Optimizing T-Cell Expansion Using DoE And Process Transfer

Manufacturing CAR-T cells is challenging, but crucial. Discover how stirred culture systems paired with an innovative platform and software can accelerate development and enhance process understanding.

Fluorescence-Based Technologies For Binding Affinity Studies

Reliable binding measurements drive research forward. Explore fluorescence techniques and optimal labeling strategies for sensitive, high-quality data crucial for discovery and cellular studies.

MOST POPULAR NEWS

Pointing The Way Towards The Future Of Drug Development

Thermo Fisher Scientific Leverages Integrated Solutions

Everest Medicines Announces NDA Approval Of VELSIPITY

Eton Pharmaceuticals Announces Submission Of NDA For ET-600 (Desmopressin Oral Solution)

Tempus Introduces Loop, An AI-Powered Target Discovery & Validation Platform

Innorna Announces FDA Rare Pediatric Disease & ODD Granted To IN013

[C.S Group] : Launches Antcin A-Based Veterinary Drug Initiative Across Taiwan And China

Sapient Launches DynamiQ As Its Next-Gen Data Insights Engine

Intellomx Launches Swarm-Based AI Platform

Silo Pharma Expands Intellectual Property Portfolio With Patent App For Alzheimer's Drug

Folia Health & Inspire Partner To Bring Personalized Home Health Observations To The Forefront Of Patient Focused Drug Dev Research

SOLUTIONS

Altasciences' Award-Winning Preclinical Research Services

Cambrex Scientist Spotlight: Kelly McGuill